New research indicates that DNA patterns might help detect the progression of certain blood cancers years before they show up in routine tests.
The study, published in the journal Cancer Discovery, tracked 30 individuals with myeloproliferative neoplasms (MPNs)—a type of blood cancer where the bone marrow produces excess blood cells. Researchers examined genetic changes in DNA from the patients’ blood and bone marrow to identify any links to blood cell counts and disease progression.
Those who maintained stability in their condition often exhibited stable DNA without significant genetic changes. Scientists at the Wellcome Trust Sanger Institute in the UK noted that these “quiet” MPNs were typically more likely to remain stable.
In contrast, patients whose conditions deteriorated often had DNA changes linked to the emergence and growth of abnormal cells, potentially years before routine blood tests indicated any problems.
Notably, nine participants eventually developed acute myeloid leukemia (AML), but their disease progression varied. In some, MPN cells gradually accumulated harmful mutations, while in others, leukemia appeared to stem from a different group of abnormal blood cells. Similar variations were observed in cases of myelofibrosis.
Moreover, the researchers noted that hydroxyurea, a medication commonly used for MPN treatment, leaves behind a specific pattern of mild DNA changes in blood cells. However, there was no evidence to suggest it causes leukemia. This pattern was also associated with azacytidine, a treatment for various blood cancers.
An interesting finding involved three participants with “triple negative” essential thrombocythemia. Although this condition is categorized as a blood cancer, their samples showed no genetic indications of cancer. This raises questions about whether some diagnosed patients might not have a malignant disease and therefore might not need long-term cancer treatments.
It’s important to note that the study’s limitations include a small sample size and the findings suggest correlations rather than direct causation.
Dr. Abhishek Chirkulwal, an oncologist at Orlando Health, mentioned that most individuals with MPN can live with the condition for decades. He remarked that this study suggests blood cancers might reveal their potential future developments through DNA changes even before symptoms manifest. He expresses that this represents a noteworthy leap toward precision medicine for blood cancer.
Another expert, not part of the study, referred to the results as a significant demonstration of how DNA changes might indicate the onset of certain cancers up to a decade prior to diagnosis. This work hints at the potential for using genetic data to predict risk many years in advance, ultimately allowing for preventive interventions instead of reactive treatments.
Chirkulwal added that continuous retesting of a patient’s DNA could help warn of concerning developments in their illness well before standard blood tests would catch them.
Looking ahead, one doctor suggested the next step could be to integrate early detection of genetic changes with targeted drugs. This approach might help prevent or slow down disease progression. He cautioned, however, that while monitoring can be useful, it doesn’t mean individuals should be preemptively evaluated for procedures like stem cell transplants unless they have clearly progressed to more severe stages of illness such as myelofibrosis or AML.
Chirkulwal concluded that this emerging research opens doors to combining early genetic detection with targeted treatments, aiming to manage the disease more effectively in the future.
